PATRICK W SMITH
CIK 1167028 · CHIEF EXECUTIVE OFFICER · last filed 2026-07-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.67B
Companies
3
Total Filings
126
Lifetime Open-Market Net
-$686.79M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AXON | CHIEF EXECUTIVE OFFICER | 3,044,897 | $547.65 | $1.67B | -$622.14M | 44 | 2026-07-09 |
| Insight Molecular Diagnostics Inc. (OCX) Delisted | 10%+ Owner | 2,872,671 | $3.20 | $9.19M | $2.45M | 5 | 2025-02-11 |
| AXON ENTERPRISE, INC. (AAXN) Delisted | CHIEF EXECUTIVE OFFICER | 370,310 | — | — | -$67.10M | 21 | 2020-12-23 |
Recent Filings · Page 3 of 13
126 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-12 | AXON | Sell (S) | −10,000 | -$8.31M | EDGAR |
| 2025-08-11 | AXON | Notice (144) | −10,000 | -$8.43M | EDGAR |
| 2025-04-23 | AXON | Sell (S) | −10,000 | -$5.41M | EDGAR |
| 2025-04-21 | AXON | Notice (144) | −10,000 | -$5.50M | EDGAR |
| 2025-03-26 | AXON | Grant (A) | +194,030 | $0 | EDGAR |
| 2025-02-11 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Mixed | +1,463,414 | $3.00M | EDGAR |
| 2025-02-04 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +915 | $1.8K | EDGAR |
| 2025-01-31 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +4,198 | $8.4K | EDGAR |
| 2025-01-15 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +16,055 | $34.1K | EDGAR |
| 2024-12-27 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +90,219 | $192.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.